Search

Your search keyword '"Kathleen Turnbull"' showing total 58 results

Search Constraints

Start Over You searched for: "Kathleen Turnbull" Remove constraint "Kathleen Turnbull"
58 results on '"Kathleen Turnbull"'

Search Results

1. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings

2. Supplementary Figure 1 from Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

3. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings

4. Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

5. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance

6. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

7. Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

8. Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

9. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

10. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

11. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

12. Symptom assessment in patients with JAK inhibitor naïve and JAK inhibitor failed myelofibrosis

13. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

14. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

15. Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

16. Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

17. Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy

18. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

19. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib

20. Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors

21. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.

23. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

24. Phi Alpha Theta Initiates.

25. The misting characteristics of spectacle lenses.

26. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.

27. Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

28. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

29. Educational program sessions.

30. WHAT'S ON: AUGUST 2017.

31. Phi Alpha Theta initiates

34. New standard focuses on quality of computer images

35. Obituaries

36. SELECT Component Factory Supports Microsoft's Visual Studio Release 6.0

37. SELECT Enterprise For Forte Strengthened Based on Customer Input; SELECT Works With Customers to Deliver Most Tightly Integrated Modeling Tool For Forte

38. Select Software Tools and Adaptive Solutions For Business Announce Partnership and Development Agreement

39. PC World Online to push daily home page delivery using Digital Bindery

40. Individual Offers Tutor For Internet Explorer 3.0

41. CAREER COACH TELLS HOW TO AVOID THE RESUME REJECT PILE

42. Individual Software Elbows Mavis Beacon

43. INDIVIDUAL SOFTWARE: ESSENTIALS YOU SHOULD KNOW WHEN BUYING SOFTWARE FOR PC USERS

44. A LIFELINE FOR WINDOWS 95 USERS

45. Individual Software's Windows 95 Tutorial CD

46. Individual Software intros Mac organizer

47. Individual in distribution deal with Zelos

48. Individual intros Multimedia Typing Instructor

49. Individual intros Peanuts family organizer

50. Professor Multimedia for the Mac intro'd

Catalog

Books, media, physical & digital resources